



MANAGING MYELOMA:

Where We Are, Where We're Going,
and Where We **SHOULD** Be Going
(Time to Choose Sides!)



David S. Siegel, MD, PhD

Founding Director, Institute for Multiple Myeloma
Hackensack Meridian Health Center for Discovery & Innovation
Chief, Multiple Myeloma Division
John Theurer Cancer Center
Hackensack University Medical Center
Hackensack, New Jersey

David S. Siegel completed his medical degree at New York University School of Medicine. His postdoctoral training included a residency in internal medicine at New York University/Bellevue Medical Center and a fellowship in hematology/oncology at Memorial Sloan Kettering Cancer Center. Dr. Siegel is one of the nation's foremost authorities on multiple myeloma. His research has almost exclusively focused on multiple myeloma, Waldenström macroglobulinemia, and amyloid light-chain amyloidosis. His research and has been published in many leading medical journals, including *Nature*, *New England Journal of Medicine*, *Blood*, and *Journal of Clinical Oncology*.

Dr. Siegel served as the lead investigator of the pivotal phase IIb study involving 30 cancer centers in North America that led to the U.S. Food and Drug Administration's fast-track approval of carfilzomib for recurrent multiple myeloma. Dr. Siegel is one of 11 investigators nationwide who brought bortezomib to multiple myeloma patients through his clinical trials, showing that this medication slows and halts the progression of multiple myeloma. He has also been involved in clinical trials that led to the approval of several other key myeloma drugs, including thalidomide, lenalidomide, pomalidomide, ixazomib, elotuzumab, and panobinostat.

Dr. Siegel and his team collaborate with other scientists and clinical researchers to pioneer critical therapies to treat patients with multiple myeloma. Dr. Siegel has led the development of a program to offer CAR T-cell therapy to patients with multiple myeloma. Dr. Siegel is also a member of the Steering Committee of the Multiple Myeloma Research Consortium, a unique research model developed to accelerate the development of novel, cutting-edge treatments for patients afflicted by multiple myeloma.